A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...

Regeneron Pharmaceuticals (REGN) shares have been in focus recently, attracting investor interest thanks to their steady ...

New details have emerged about what Regeneron is planning for the Saratoga Springs site it acquired last year.

In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

Williams & Connolly, a General Litigation Department of the Year finalist, notched several victories before the U.S. Supreme ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Prospera Financial Services acquires Regeneron Pharmaceuticals (REGN) shares, reflecting healthcare sector activity aligned ...